^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iNeo-Vac-P01

    i
    Other names: iNeo-Vac-P01
    Associations

    News

    Trials
    Company:
    Hangzhou Neoantigen Therap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2d
    Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Active, not recruiting | N=40 --> 27 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    iNeo-Vac-P01
    4ms
    Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Zhejiang University
    New P1/2 trial
    |
    cyclophosphamide • iNeo-Vac-P01
    4years
    A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. (PubMed, Front Immunol)
    As one of the earliest studies that addressed an issue in treating pancreatic cancer with personalized vaccines, it has been demonstrated that iNeo-Vac-P01, a personalized neoantigen-based peptide vaccine, could improve the currently limited clinical efficacy of pancreatic cancer. ClinicalTrials.gov, identifier (NCT03645148).Registered August 24, 2018 - Retrospectively registered.
    Clinical • Retrospective data • Journal • Tumor Mutational Burden
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    TMB-L
    |
    iNeo-Vac-P01
    over4years
    Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Sir Run Run Shaw Hospital
    Clinical • New P1 trial • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    iNeo-Vac-P01